Editorial

Suggested evaluation of biological drugs role for WHO – Editor’s response

Published in: Volume 2 / Year 2013 / Issue 4
Author(s):
Page: 162

Abstract: The Editor-in-Chief expresses his concerns about the proposal of a WHO run system to approve copy biologicals in the Milani and Gaspani paper [1]. The paper by Milani and… Read More »

Italy’s final position paper on biosimilars and new price and reimbursement pathway

Published in: Volume 2 / Year 2013 / Issue 3
Author(s):
Page: 106-7

Abstract: The AIFA’s position paper recognizes the relevance of biosimilars to ensure the sustainability of drug expenditure but the new price and reimbursement procedure may not favour their prompt market… Read More »

National and regional activities by sickness funds in Austria to encourage the rational use of medicines

Published in: Volume 2 / Year 2013 / Issue 2
Author(s):
Page: 58-9

Abstract: Dr Brian Godman reviews the paper by Vogler and Zimmermann on sickness fund activity in Austria to preferentially encourage the prescribing of generics. This is particularly important given the… Read More »

Health authority perspective on biosimilars

Published in: Volume 2 / Year 2013 / Issue 1
Author(s):
Page: 10-11

Abstract: Dr Brian Godman reviews Mr Gustaf Befrits’ paper on the case for biosimilars from a payer’s perspective. Biosimilars are increasingly important to payers with growing resource pressures. However, key… Read More »

Reference price systems: stakeholder dialogue and involvement

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s):
Page: 114-5

Abstract:  Dylst et al. provide a detailed overview about the characteristics of reference price systems in Europe and discuss their possible impact. The role of stakeholders in the implementation of… Read More »

Generics policies–a globally-relevant implementation challenge

Published in: Volume 1 / Year 2012 / Issue 3-4
Author(s):
Page: 113-4

Abstract:  Vogler and Zimmerman, reporting on the 2011 Pharmaceutical Pricing and Reimbursement Information (PPRI) Conference, have noted the incomplete application of generics policies in many settings, and have called for… Read More »

Equal protection under the law: Children and the Best Pharmaceuticals for Children Act

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 54-5

Abstract:  Four changes to the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act will markedly improve these programmes: expanded attention paid to neonatal studies, support for the… Read More »

Generic medicine pricing: on track in Europe?

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 5

Abstract:  There are many variables responsible for the pricing of generic medicines in Europe. This editorial looks at the many policy initiatives currently being undertaken. Submitted: 3 November 2011; Revised… Read More »

Non-Biological Complex Drugs

Read More »

Page 2 of 2 « Previous1 2
Go Back Print